Taxing drugs won’t help wealthy addicts

Supporters of drug decriminalisation are mobilising en masse at present, attempting to force a radical overhaul of Britain’s drugs policy. Critics have lambasted current legislation for its role in increasing crime and damaging public health, promoting decriminalisation as the perfect tonic for curing society’s ills.

It is worth remembering, however, that drugs are not simply the scourge of the poor, nor is their usage restricted to estates and inner cities across the country.

Drugs blight lives across the social spectrum, with the class divide meaning little when it comes to the vice-like grip in which addiction holds countless Britons. Growing up in one of London’s most salubrious suburbs, my friends and I were exposed to drugs on a round-the-clock basis at times, despite seemingly having it all in terms of money and privilege.

Likewise, during my days in the Square Mile, a culture of excess and hedonism reigned, thanks to the narcissistic and self-indulgent nature of the City beast at whose altar we all worshipped. Largesse and greed coursed through the veins of market players across the board, and drugs and drink were two easy ways in which to satiate one’s lust for high living.

Drug abuse was a far less prominent phenomenon than excessive alcohol consumption, largely because of the ramifications for any trader or broker caught high during office hours. Three-hour, booze-fuelled lunches were the norm for bosses and subordinates alike, yet coke-connoisseurs such as myself and my friends had to restrict our intake to nocturnal gatherings for fear of the consequences of being caught. As such, our habits didn’t get even more out of control than they already were, and we were forced to self-regulate our consumption.

Grandiose ideas such as withdrawing benefits for drug users who refuse treatment for their addiction will have no impact on such “high-end” users, for whom money is no object when it comes to supporting their illicit habits. Similarly, the price of the product being consumed makes little difference to those with copious amounts of disposable income at hand: we brokers happily paid £50 a gram to satisfy our craving; we’d have just as gladly paid double or triple should market forces have demanded us to do so. Addicts cannot be simply priced or taxed out of their habits; instead, the onus should be on reducing demand via educational and psychological means.

I underwent just such a remedial process, which was wholly effective in getting me off drugs for good. Once I realised that there was far more to life than a perpetual cycle of money worship by day, hard drugs by night, and little to no structure past the next trade I put on or the next gram I scored, I was able to consign coke to my past and move onwards and upwards in terms of living a far more fulfilling life in which drugs played no part.

In an ideal world, both drugs and drink would be unnecessary evils for all citizens, and the issue of their legality neither here nor there. In the real world, however, there should be a concerted effort to keep drugs as far out of reach as possible, if only to prevent their further encroachment into previously safe terrain, whether that be a Bethnal Green council flat or a Bishops Avenue summer palace.

That the global war on drugs is not working is a sad fact of life, but throwing in the towel is not the answer. Moral positions should not get turned on their head just to satisfy short-termist lawmakers and lobbyists; instead, a more concerted effort must be made to stop disaffected citizens running into the welcoming arms of their local drug dealers.

Drug usage can be curtailed by effective education and provision of alternative pastimes – a strategy infinitely preferable to exposing society to an even headier cocktail of substances than are already on offer.

Via: guardian.co.uk

Devon man and Bristol woman arrested over drug find

Two people have been arrested after police stopped a car in Devon and found drugs inside with an estimated street value of £6,000.

Officers stopped the vehicle on the M5 on Friday afternoon and discovered cannabis and an amount of powder – believed to be controlled drugs.

More suspected drugs were found when they searched an address in east Devon.

A man from east Devon and a woman from Bristol, both 45, were arrested and bailed until 6 November.

Via: bbc.co.uk

Drug firm slashes prices after MoS investigation -saving taxpayer £500k

A drugs company under scrutiny for increasing the price the NHS pays for lifesaving pills by 1,000 per cent in two years has dramatically cut its charges after a Mail on Sunday investigation.

The firm slashed the price of its hydrocortisone tablets, used to treat kidney patients, by £7.40 – saving the NHS almost £500,000 on its monthly drugs bill.

The company’s boss had claimed the NHS ‘doesn’t care what it costs’ when he was asked to explain the price increases passed on to the taxpayer.

The price cut came as the Department of Health admitted it does not police the cost of everyday medicines supplied to the NHS.
Despite claims of profiteering on some commonly prescribed drugs, civil servants said the department ‘does not regulate generic prices’.

The Mail on Sunday investigation revealed how some pharmaceutical companies were imposing huge price increases while earning massive profits. Drugs firm Auden McKenzie was charging £44.40 for a packet of its 10mg hydrocortisone tablets, but on Monday – the day after our investigation was published – the company wrote to wholesalers cutting the price to £37 with immediate effect.

The firm had increased the price of the tablets for the NHS from £5 in 2008 to a peak of £48 earlier this year – making it about £2.4 million a month.

Company boss Amit Patel, 35, whose personal wealth is said to exceed £40 million, claimed the price rises were needed to pay for his firm’s new multi-million-pound factory production line.

He refused to say where the factory was or give any further details and said the price of the drugs would ‘creep back down’ because the firm had recouped much of its outlay.

In a previous interview with The Mail on Sunday, he said: ‘Joe Public doesn’t know what it takes to . . . revive these old drugs. Quite rightly . . . the Government views medicine as public safety, so they don’t care what it costs.’

He added: ‘To be honest, they don’t care what it costs. You either meet their criteria or you don’t market the product.’

Last week, he issued a statement denying that he had claimed the ‘NHS doesn’t care what drugs cost’ and saying he ‘strenuously denies ever discussing the production costs of the drug’.

Questions to Auden McKenzie’s media advisers asking for the reasons for the reduction in the price of the tablets went unanswered yesterday.

Between 2007 and 2008, the firm’s turnover rose from £5.3 million to £10.6 million and its profits trebled to £6.2 million.

Details of its more recent accounts – which coincide with the increased price of hydrocortisone – are not available and are listed as overdue by Companies House.

Via: dailymail.co.uk

‘Brits being denied crucial cancer drugs to save money’

London, July 26 (ANI): A new report is set to reveal that thousands of Britons are being denied access to drugs crucial in cancer treatments.

The UK’s breast cancer patients have 50 percent less chance of the drug Herceptin than elsewhere in Europe.

The report, commissioned by the Department of Health will put pressure on the Government to speed up plans for a 200 million pounds cancer fund that would allow patients to get access to new drugs not currently approved for NHS use.

“It is high time we had a review of access to new drugs. However, I doubt that the 200million pound cancer fund would make us as good as the best countries in the report. We would need around £billion to achieve that,” The Daily Express quoted leading cancer specialist Karol Sikora from Cancer Partners UK, as saying.

“Patients in the UK have poorer access to Alzheimer’s drugs, Multiple Sclerosis drugs and Rheumatoid Arthritis drugs too. It all needs to be looked at,” he added.

Allegedly, the National Institute for Health and Clinical Excellence or NICE has blocked a number of medicines, on grounds of cost, that can extend the lives of those battling more unusual forms of cancer.

NICE has restricted access to the bowel cancer drug Avastin, and Nexavar, the only treatment offering any chance of survival for patients with advanced liver cancer.

NICE agrees the drugs can alleviate symptoms but says the NHS cannot afford them.

The outcry against negative decisions has led to a review by NICE into a controversial decision to block one new bone marrow drug called Azacitidine.

One of the groups suffering most are 400 liver cancer patients denied Nexavar to shrink their tumours and give them the chance of potentially life-saving surgery.

Ian Beaumont, of Bowel Cancer UK, said that for some patients even a few months delay “means the difference between life and death.” (ANI)

Via: newstrackindia.com

A career built on bringing lifesaving drugs to the market and to patients

In college, I fell in love with the notion of correcting a disease and making a person better by giving them a pharmaceutical. I thought it would be satisfying enough to be a researcher, until I got into graduate school and saw that I wanted to be the one giving the agents and seeing the response.

I didn’t even know what pharmacology was until my third year of college. My chemistry professor saw that I was interested in physiology and biochemistry. It struck a chord with me to merge those two disciplines and apply it to the human disease condition.

So I decided I wanted to become a clinical pharmacologist, which is essentially a drug development expert. The Navy put me through medical school, and upon graduating, I worked as a primary-care doctor for two years on a ship with 600 other men. I also began my research work in the Navy.

It was during the time of the 1991 Persian Gulf War, after Iraq’s Saddam Hussein had invaded Kuwait. Heat stress was a problem for the troops in the desert. I studied to see if there was a way to decrease the body temperature of the soldiers if they got overheated. We found some medicines that would be safe and effective.

Eventually, I became intrigued by the Food and Drug Administration and its power to make decisions on medicines. It’s one thing to be writing the book, but the FDA gets to be the book critic, so to speak.

I spent six years there working in infectious disease or oncology review. The neat thing about being a clinical pharmacologist is that it’s a broad specialty that lets you be involved with different types of products.

I was on the receiving end of two applications that ended up being approved by the FDA. One treated the infectious disease hepatitis C, and the other treated colon cancer. That was my proudest work — to be on the team that approves a new product that allows people to live longer.

I left the FDA and went into industry, working at various companies in vaccines and products for infectious disease and oncology. I was positioned at the very end of development and application for FDA approval.

Via: washingtonpost.com